Moderate

VTE prophylaxis in hospitalised patients (hospital thromboprophylaxis; medical & surgical inpatients, VTE risk assessment)

Prevention / inpatient · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hospital-acquired venous thromboembolism (HA-VTE) is a major preventable cause of inpatient morbidity and mortality. Every patient admitted should have a documented VTE risk assessment balanced against bleeding risk, and appropriate pharmacological and/or mechanical prophylaxis started promptly and reviewed regularly. LMWH is the default pharmacological agent in most inpatients.

Red flags

  • Signs of established VTE: unilateral painful swollen leg (DVT), pleuritic chest pain/dyspnoea/hypoxia/tachycardia (PE) — investigate and treat, do not just continue prophylaxis
  • Active major bleeding or rapidly falling platelets on heparin (suspect HIT) — stop heparin, investigate
  • Platelets <50 or coagulopathy — reassess/avoid pharmacological prophylaxis
  • Imminent neuraxial procedure — ensure correct timing interval

Assessment

Differential diagnosis

  • Assess VTE risk factors: acute medical illness with reduced mobility, surgery (esp. orthopaedic/pelvic/cancer), active cancer, previous VTE, thrombophilia, age >60, obesity, pregnancy/puerperium, oestrogen therapy, dehydration, sepsis, central venous catheter
  • Assess bleeding risk: active bleeding, acquired/inherited bleeding disorder, platelets <50, thrombocytopenia, concurrent anticoagulant, uncontrolled hypertension, recent intracranial bleed/surgery, lumbar puncture/epidural within 4 h, acute stroke, hepatic failure

Investigations

  • Documented VTE + bleeding risk assessment on admission and within 24 h / at consultant review (NICE NG89)
  • FBC (platelets), U&E/eGFR (LMWH dose adjustment / anti-Xa if extremes of weight or renal impairment), coagulation screen
  • Weight (dose banding at extremes of body weight)
  • Reassess risk if clinical condition changes, at 24 h and when prophylaxis status changes

Management

  • Assess ALL admitted patients for VTE risk and bleeding risk, and document it
  • If VTE risk outweighs bleeding risk: start pharmacological prophylaxis as soon as possible and within 14 hours of the decision
  • Choose agent: LMWH first-line for most; fondaparinux if LMWH contraindicated; UFH if severe renal impairment (eGFR <15-30); DOAC/LMWH per pathway for elective hip/knee arthroplasty
  • If pharmacological prophylaxis contraindicated or patient declines: offer mechanical prophylaxis (intermittent pneumatic compression, or anti-embolism stockings) unless contraindicated (e.g. peripheral arterial disease, leg oedema from heart failure, local leg condition)
  • Encourage mobilisation and hydration; avoid dehydration
  • Review prophylaxis daily — continue until mobility restored / discharge; extend for selected high-risk groups (e.g. 28-35 days after hip fracture / hip or abdominopelvic cancer surgery)
  • Give the patient/carer verbal and written information on VTE signs and prophylaxis
  • Hold/time prophylaxis appropriately around neuraxial anaesthesia and procedures

Drugs & doses

Enoxaparin 40 mg SC once daily (standard prophylactic dose; reduce to 20 mg once daily if eGFR <30 or low weight; higher dose banding if high body weight) [verify local dose]
Dalteparin 5000 units SC once daily (standard prophylactic dose) [verify local dose]
Tinzaparin 3500-4500 units SC once daily [verify local dose]
Unfractionated heparin 5000 units SC twice or three times daily — preferred in severe renal impairment (eGFR <15-30) [verify local dose]
Fondaparinux 2.5 mg SC once daily (if LMWH contraindicated; avoid if eGFR <20) [verify local dose]
Elective hip/knee arthroplasty extended prophylaxis: e.g. apixaban 2.5 mg PO twice daily, rivaroxaban 10 mg PO once daily, dabigatran, or LMWH per NICE NG89 pathway [verify local]
Mechanical: intermittent pneumatic compression device; anti-embolism (graduated compression) stockings — NOT in acute stroke, PAD, or significant leg oedema

Disposition

Inpatient process. Continue until mobile/discharged; arrange extended prophylaxis supply and teaching for high-risk surgical groups. Document VTE assessment for every admission.

Complications & pitfalls

  • Bleeding (major/minor) from pharmacological prophylaxis
  • Heparin-induced thrombocytopenia (HIT) — check platelets
  • Skin/pressure damage, arterial compromise from stockings in PAD
  • Breakthrough VTE despite prophylaxis (consider dose adequacy at weight extremes/renal impairment)

Exam pearls

  • Guideline: NICE NG89 (VTE in over-16s: reducing the risk of hospital-acquired DVT or PE). Use the national VTE risk assessment tool.
  • LMWH is weight- and renal-dependent — adjust at extremes of body weight and in renal impairment; consider anti-Xa monitoring.
  • Mechanical prophylaxis is the fallback when anticoagulation is contraindicated — but check for PAD and heart-failure leg oedema first.
  • Extended prophylaxis (28-35 days) is indicated after hip fracture and major abdominopelvic cancer / hip or knee arthroplasty.
  • Reassess within 24 hours — a patient's VTE and bleeding balance changes quickly in hospital.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.